New hope for tough lymphoma: experimental drug AZD4512 enters human trials
NCT ID NCT07123454
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 27 times
Summary
This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part across multiple centers worldwide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGIrvine, California, 92618, United States
-
Research Site
RECRUITINGJacksonville, Florida, 32224, United States
-
Research Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Research Site
RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGNew York, New York, 10021, United States
-
Research Site
WITHDRAWNCleveland, Ohio, 44195, United States
-
Research Site
WITHDRAWNMyrtle Beach, South Carolina, 29572, United States
-
Research Site
RECRUITINGFranklin, Tennessee, 37067, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
NOT_YET_RECRUITINGChengdu, 610041, China
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510060, China
-
Research Site
RECRUITINGBologna, 40138, Italy
-
Research Site
RECRUITINGMilan, 20133, Italy
-
Research Site
RECRUITINGMilan, 20141, Italy
-
Research Site
RECRUITINGBunkyō City, 113-8677, Japan
-
Research Site
RECRUITINGKōtoku, 135-8550, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
RECRUITINGTaichung, 40705, Taiwan
-
Research Site
RECRUITINGTaipei, 106, Taiwan
-
Research Site
RECRUITINGLondon, W1T 7HA, United Kingdom
-
Research Site
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.